A Common Phosphotyrosine Signature for the Bcr-Abl Kinase

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2006 Feb 25

PMID 16497976

Citations 42

Authors

Valerie L Goss

Kimberly A Lee

Albrecht Moritz

Julie Nardone

Erik J Spek

Joan MacNeill

John Rush

Michael J Comb

Roberto D Polakiewicz

Affiliations

Soon will be listed here.

Abstract

The Bcr-Abl fusion kinase drives oncogenesis in chronic myeloid leukemia (CML). CML patients are currently treated with the Abl tyrosine kinase inhibitor imatinib, which is effective in early stages of the disease. However, resistance to imatinib arises in later disease stages primarily because of a Bcr-Abl mutation. To gain deeper insight into Bcr-Abl signaling pathways, we generated phosphotyrosine profiles for 6 cell lines that represent 3 Bcr-Abl fusion types by using immunoaffinity purification of tyrosine phosphopeptides followed by tandem mass spectrometry. We identified 188 nonredundant tyrosine-phosphorylated sites, 77 of which are novel. By comparing the profiles, we found a number of phosphotyrosine sites common to the 6 cell lines regardless of cellular background and fusion type, several of which are decreased by imatinib treatment. Comparison of this Bcr-Abl signature with the profile of cells expressing an alternative imatinib-sensitive fusion kinase, FIP1L1-PDGFRalpha, revealed that these kinases signal through different pathways. This phosphoproteomic study of the Bcr-Abl fusion kinase highlights novel disease markers and potential drug-responsive biomarkers and adds novel insight into the oncogenic signals driven by the Bcr-Abl kinase.

Citing Articles

MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia.

Mazzera L, Abeltino M, Lombardi G, Cantoni A, Jottini S, Corradi A Leukemia. 2023; 37(8):1671-1685.

PMID: 37386079 PMC: 10400427. DOI: 10.1038/s41375-023-01940-x.

Regulation of Beclin 1-Mediated Autophagy by Oncogenic Tyrosine Kinases.

Vega-Rubin-de-Celis S, Kinch L, Pena-Llopis S Int J Mol Sci. 2020; 21(23).

PMID: 33287140 PMC: 7729755. DOI: 10.3390/ijms21239210.

Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets.

Adnan-Awad S, Kim D, Hohtari H, Javarappa K, Brandstoetter T, Mayer I Leukemia. 2020; 35(7):1964-1975.

PMID: 33168949 PMC: 8257498. DOI: 10.1038/s41375-020-01082-4.

Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of....

Klumper T, Bruckmueller H, Diewock T, Kaehler M, Haenisch S, Pott C Exp Hematol Oncol. 2020; 9:26.

PMID: 32999756 PMC: 7519530. DOI: 10.1186/s40164-020-00183-1.

Response and Resistance to BCR-ABL1-Targeted Therapies.

Braun T, Eide C, Druker B Cancer Cell. 2020; 37(4):530-542.

PMID: 32289275 PMC: 7722523. DOI: 10.1016/j.ccell.2020.03.006.

References

Kirsch K, Georgescu M, Shishido T, Langdon W, Birge R, Hanafusa H . The adapter type protein CMS/CD2AP binds to the proto-oncogenic protein c-Cbl through a tyrosine phosphorylation-regulated Src homology 3 domain interaction. J Biol Chem. 2000; 276(7):4957-63. DOI: 10.1074/jbc.M005784200. View

Druker B, Sawyers C, Kantarjian H, Resta D, Reese S, Ford J . Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344(14):1038-42. DOI: 10.1056/NEJM200104053441402. View

Ikuno Y, Leong F, Kazlauskas A . PI3K and PLCgamma play a central role in experimental PVR. Invest Ophthalmol Vis Sci. 2002; 43(2):483-9. View

Sawyers C, Hochhaus A, Feldman E, Goldman J, Miller C, Ottmann O . Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002; 99(10):3530-9. DOI: 10.1182/blood.v99.10.3530. View

ODwyer M, La Rosee P, Nimmanapalli R, Bhalla K, Druker B . Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide. Semin Hematol. 2002; 39(2 Suppl 1):18-21. DOI: 10.1053/shem.2002.33612. View

Sattler M, Mohi M, Pride Y, Quinnan L, Malouf N, Podar K . Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell. 2002; 1(5):479-92. DOI: 10.1016/s1535-6108(02)00074-0. View

Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T . Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene. 2002; 21(38):5868-76. DOI: 10.1038/sj.onc.1205724. View

Shah N, Nicoll J, Nagar B, Gorre M, Paquette R, Kuriyan J . Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002; 2(2):117-25. DOI: 10.1016/s1535-6108(02)00096-x. View

Salomon A, Ficarro S, Brill L, Brinker A, Phung Q, Ericson C . Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry. Proc Natl Acad Sci U S A. 2003; 100(2):443-8. PMC: 141014. DOI: 10.1073/pnas.2436191100. View

10.

Cools J, DeAngelo D, Gotlib J, Stover E, Legare R, Cortes J . A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348(13):1201-14. DOI: 10.1056/NEJMoa025217. View

11.

Ong S, Kratchmarova I, Mann M . Properties of 13C-substituted arginine in stable isotope labeling by amino acids in cell culture (SILAC). J Proteome Res. 2003; 2(2):173-81. DOI: 10.1021/pr0255708. View

12.

Steen H, Fernandez M, Ghaffari S, Pandey A, Mann M . Phosphotyrosine mapping in Bcr/Abl oncoprotein using phosphotyrosine-specific immonium ion scanning. Mol Cell Proteomics. 2003; 2(3):138-45. DOI: 10.1074/mcp.M300001-MCP200. View

13.

Griffin J, Leung J, Bruner R, Caligiuri M, Briesewitz R . Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A. 2003; 100(13):7830-5. PMC: 164673. DOI: 10.1073/pnas.0932698100. View

14.

Huber T, Hartleben B, Kim J, Schmidts M, Schermer B, Keil A . Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling. Mol Cell Biol. 2003; 23(14):4917-28. PMC: 162232. DOI: 10.1128/MCB.23.14.4917-4928.2003. View

15.

Deininger M, Druker B . Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev. 2003; 55(3):401-23. DOI: 10.1124/pr.55.3.4. View

16.

Ibarrola N, E Kalume D, Gronborg M, Iwahori A, Pandey A . A proteomic approach for quantitation of phosphorylation using stable isotope labeling in cell culture. Anal Chem. 2003; 75(22):6043-9. DOI: 10.1021/ac034931f. View

17.

Mohi M, Boulton C, Gu T, Sternberg D, Neuberg D, Griffin J . Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A. 2004; 101(9):3130-5. PMC: 365755. DOI: 10.1073/pnas.0400063101. View

18.

Woodring P, Meisenhelder J, Johnson S, Zhou G, Field J, Shah K . c-Abl phosphorylates Dok1 to promote filopodia during cell spreading. J Cell Biol. 2004; 165(4):493-503. PMC: 2172353. DOI: 10.1083/jcb.200312171. View

19.

Hornbeck P, Chabra I, Kornhauser J, Skrzypek E, Zhang B . PhosphoSite: A bioinformatics resource dedicated to physiological protein phosphorylation. Proteomics. 2004; 4(6):1551-61. DOI: 10.1002/pmic.200300772. View

20.

Cooper J, Sefton B, Hunter T . Detection and quantification of phosphotyrosine in proteins. Methods Enzymol. 1983; 99:387-402. DOI: 10.1016/0076-6879(83)99075-4. View